On October 11, CVS Health touched its 11-month low and traded at $73.90. The company has lost 6.3% year-to-date.
Wall Street analysts are projecting 11.2% earnings growth for Walgreens over the next year.
Walgreens’ US Retail Pharmacy business, which generates more than 70% of the company’s total sales, has enjoyed decent sales growth. Its top line improved 3.1% in the first nine months of fiscal 2016.
In August 2016, Walgreens announced a long-term strategic alliance with Prime Therapeutics, America’s fourth-largest PBM.
CVS generates close to 70% of its annual sales by offering a full range of pharmacy benefit management services.
The US is Walgreens’ largest market and accounts for more than 70% of its total sales and operating income.
The US drugstore market is dominated by two major players—CVS Health (CVS) and Walgreens Boots Alliance (WBA). CVS and WBA accounted for ~29% of the country’s prescription dispensing revenues in 2016.
The majority of analysts covering Walmart (WMT) stock continue to have a neutral stance on the company’s prospects. About 50.0% of them have rated the stock a “hold.”
Walmart’s (WMT) e-commerce sales rose 60.0% in fiscal 2Q18 compared to a rise of 63.0% in fiscal 1Q18.
Walmart (WMT) stock rose 4.5% on Tuesday, October 10, 2017, following the company’s upbeat outlook for fiscal 2019. Walmart expects both its top and bottom lines to improve in fiscal 2019.
In its most recent move, Walmart will offer a returns service, Mobile Express Returns, for products sold and shipped by Walmart.com.
Constellation Brands’ (STZ) 12-month forward PE (price-to-earnings) ratio fell 1.4% to 24.0x on October 5, 2017, the day the company announced its fiscal 2Q18 results.
As of October 6, 2017, 13 of the 19 analysts (or 68.0%) covering Constellation Brands (STZ) stock had “buy” ratings for the stock. Six analysts recommended a “hold.”
Constellation Brands’ (STZ) gross margin increased to 51.1% in fiscal 2Q18 from 47.9% in fiscal 2Q17.
Constellation Brands’ (STZ) beer segment accounted for 66.2% of the company’s net sales in fiscal 2Q18, which ended on August 31, 2017.
Constellation Brands (STZ) generated sales of $2.09 billion in fiscal 2Q18, exceeding the consensus analysts’ sales estimate of $2.06 billion.
Constellation Brands (STZ) delivered adjusted EPS of $2.47 in fiscal 2Q18, handily exceeding the consensus Wall Street analysts’ earnings estimate of $2.16 per share.
Constellation Brands (STZ) stock rose 4.0% on October 5, 2017, in reaction to the company’s results for fiscal 2Q18, which ended August 31, 2017.
Through its recently announced Mobile Express Returns service, Walmart is reducing the hassles of returns and refunds by fast-tracking the process and leveraging its strong stores base.
Analysts Ana Gupte of Leerink Partners said in a recent client note that Amazon might enter the drug distribution market within the next two years.